Risk factor
Poor trading liquidity
Profitability factor
Greatly overvalued vs peers
About
Operating primarily within India, Orchid Pharma Limited is a pharmaceutical firm specializing in the creation, production, and commercialization of active pharmaceutical ingredients (APIs), finished dosage forms (FDFs), and nutraceutical products. Its comprehensive API portfolio encompasses oral and injectable cephalosporins, various veterinary pharmaceuticals, and non-antibiotic substances. The company maintains a multi-faceted therapeutic footprint, with offerings in areas such as anti-infectives, anti-inflammatory agents, central nervous system disorders, cardiovascular health, and nutraceuticals, alongside other oral and sterile formulations. Furthermore, it provides sophisticated new drug discovery (NDD) and pharmaceutical research and development (R&D) services. Orchid Pharma also engages in global trade, distributing its products to roughly 40 nations worldwide. Additionally, it offers comprehensive liaison and support services to its clientele, covering areas like regulatory compliance, pharmacovigilance, product testing and release, sample retention, coordination with service providers, and business expansion initiatives. The entity, originally incorporated as Orchid Chemicals & Pharmaceuticals Limited, adopted its current name, Orchid Pharma Limited, in October 2015. Established in 1992, its corporate headquarters are situated in Chennai, India. The company operates as a subsidiary of Dhanuka Laboratories Limited.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is overpriced on P/E, 'expensive
Target Price
The average target price of ORCHPHARMA.NS is 928 and suggests 6.1% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendati